{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"46.5","upperLimit":"100","value":"64.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"35"}],"units":"Participants"}],"description":"will be evaluated in this study using the new international criteria proposed by the revised Response Evaluation Criteria in Solid Tumors (RECIST) guideline (version 1.1)","dispersionType":"97.5% Confidence Interval","groups":[{"description":"Nivolumab treatment: Nivolumab 480 mg IV once every 4 weeks. Treatment will continue until time of disease progression or until development of unacceptable toxicity, whichever comes first.\n\nNivolumab: Nivolumab 480 mg IV once every 4 weeks","id":"OG000","title":"Nivolumab"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"at 24 weeks","title":"Progression-Free Survival","type":"PRIMARY","unitOfMeasure":"percentage of patients"}